Phathom Pharmaceuticals (Phathom Pharmaceuticals) FCF Margin % : -6,491.50% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Phathom Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $-44.27 Mil. Phathom Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.68 Mil. Therefore, Phathom Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -6,491.50%.

As of today, Phathom Pharmaceuticals's current FCF Yield % is -26.04%.

The historical rank and industry rank for Phathom Pharmaceuticals's FCF Margin % or its related term are showing as below:

PHAT' s FCF Margin % Range Over the Past 10 Years
Min: -20412.61 Med: -20412.61 Max: -20412.61
Current: -20412.61

During the past 6 years, the highest FCF Margin % of Phathom Pharmaceuticals was -20412.61%. The lowest was -20412.61%. And the median was -20412.61%.

PHAT's FCF Margin % is ranked worse than
94% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs PHAT: -20412.61

Phathom Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Phathom Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals FCF Margin % Chart

Phathom Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-20,412.61

Phathom Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-6,491.50

Competitive Comparison of Phathom Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Phathom Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phathom Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's FCF Margin % falls into.

Phathom Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Phathom Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-139.214	/	0.682
	=	-20,412.61 %

Phathom Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-44.272	/	0.682
	=	-6,491.50 %

Phathom Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Phathom Pharmaceuticals (Phathom Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932

Website

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Executives

Molly Henderson	officer: CFO and CBO	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Asit Parikh	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Azmi Nabulsi	officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
David A Socks	director, officer: President, CEO, Treas. & Sec.	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo	officer: VP, Chief Accounting Officer	C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse	director	5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola	director	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116